For β blockers and thiazide diuretics, although there is no certainty about the biological pathway for diabetes risk, studies have suggested that modification of insulin secretion and carbohydrate metabolism in β blockers,48, 49 and potassium depletion in thiazide diuretics50 could play a role. The gene discussed is INS; the disease is diabetes mellitus.